Differential musculoskeletal outcome reporting in patients receiving bempedoic acid or atorvastatin: a disproportionality analysis using the EudraVigilance database

BackgroundElevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease. Statins are the first choice LDL-C-lowering drugs, but often associated with musculoskeletal disorders (MSDs), limiting adherence. Bempedoic acid (BA) is a newer LDL-C-lo...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Gianluca Gazzaniga, Antonio Romio, Chiara Galuppi, Elena Gentile, Filomena Valentino, Luca De Toni, Michela Foschiatti, Michele Gringeri, Stefano D’Onghia, Danilo Menichelli, Daniele Pastori, Marco Scatigna, Diego Maria Michele Fornasari, Stefano Grosdani, Arianna Pani
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2026-01-01
Seria:	Frontiers in Pharmacology
Hasła przedmiotowe:	adverse drug reactions atorvastatin bempedoic acid cardiovascular drug safety pharmacovigilance
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1736657/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!